India plans to diversify pharma exports beyond the U.S., targeting semi-regulated markets in Africa, Latin America, and Southeast Asia. Pharmexcil is boosting sales to China to help reduce the $99.2 billion trade deficit, while tariff uncertainty in the U.S. remains a key concern.
Source link